Volume 16, Issue 8, Pages (August 2015)

Slides:

Advertisements

Similar presentations

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.

Advertisements

Volume 14, Issue 12, Pages (November 2013)

Volume 14, Issue 4, Pages (April 2013)

Volume 12, Issue 9, Pages (September 2011)

Volume 16, Issue 2, Pages (February 2015)

Volume 12, Issue 11, Pages (October 2011)

Volume 383, Issue 9928, Pages (May 2014)

Volume 15, Issue 6, Pages (May 2014)

Volume 386, Issue 9992, Pages (August 2015)

Volume 14, Issue 10, Pages (September 2013)

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9783, Pages (June 2011)

Volume 384, Issue 9952, Pages (October 2014)

Volume 16, Issue 8, Pages (August 2015)

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Volume 15, Issue 2, Pages (February 2014)

Volume 14, Issue 4, Pages (April 2015)

A Randomized, Double-Blind, Placebo-Controlled Trial of Nutritional Supplementation During Acute Illness Salah Gariballa, MD, Sarah Forster, MSc, Stephen.

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical.

Volume 15, Issue 4, Pages (April 2014)

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Volume 15, Issue 4, Pages (April 2014)

Volume 12, Issue 7, Pages (July 2011)

Volume 15, Issue 6, Pages (May 2014)

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Volume 18, Issue 3, Pages (March 2017)

Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label,

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Volume 387, Issue 10023, Pages (March 2016)

Volume 6, Issue 6, Pages (June 2005)

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Volume 389, Issue 10073, Pages (March 2017)

Volume 14, Issue 6, Pages (May 2013)

Volume 386, Issue 9992, Pages (August 2015)

Volume 14, Issue 11, Pages (October 2013)

Volume 385, Issue 9962, Pages (January 2015)

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,

Volume 19, Issue 4, Pages (April 2018)

Volume 15, Issue 12, Pages (November 2014)

Volume 2, Issue 5, Pages (May 2015)

Volume 16, Issue 15, Pages (November 2015)

A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):

Volume 15, Issue 6, Pages (May 2014)

Volume 14, Issue 6, Pages (May 2013)

Volume 16, Issue 15, Pages (November 2015)

Neuromuscular electrical stimulation to improve exercise capacity in patients with severe COPD: a randomised double-blind, placebo-controlled trial Dr.

Volume 5, Issue 4, Pages (April 2018)

Volume 383, Issue 9928, Pages (May 2014)

Standard versus Dose-Intensified Chemotherapy with Sequential Reinfusion of Hematopoietic Progenitor Cells in Small Cell Lung Cancer Patients with Favorable.

Volume 15, Issue 6, Pages (May 2014)

Volume 15, Issue 1, Pages (January 2014)

Volume 15, Issue 8, Pages (July 2014)

Volume 12, Issue 8, Pages (August 2013)

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial Dr David Preiss, PhD, Suzanne M Lloyd,

Volume 2, Issue 10, Pages (October 2015)

Volume 18, Issue 10, Pages (October 2017)

A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Volume 14, Issue 9, Pages (August 2013)

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North.

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

Volume 14, Issue 7, Pages (June 2013)

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer Giorgio.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell.

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.

Presentation transcript:

Volume 16, Issue 8, Pages 967-978 (August 2015) Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial Prof Juan W Valle, MD, Harpreet Wasan, MD, Andre Lopes, MSc, Alison C Backen, PhD, Prof Daniel H Palmer, PhD, Karen Morris, PhD, Marian Duggan, MSc, Prof David Cunningham, MD, D Alan Anthoney, MD, Pippa Corrie, MD, Srinivasan Madhusudan, MD, Prof Anthony Maraveyas, MD, Paul J Ross, MD, Justin S Waters, PhD, Prof Will P Steward, PhD, Charlotte Rees, MD, Sandy Beare, PhD, Prof Caroline Dive, PhD, John A Bridgewater, MD The Lancet Oncology Volume 16, Issue 8, Pages 967-978 (August 2015) DOI: 10.1016/S1470-2045(15)00139-4 Copyright © 2015 Valle et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 1 Trial profile The Lancet Oncology 2015 16, 967-978DOI: (10.1016/S1470-2045(15)00139-4) Copyright © 2015 Valle et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 2 Kaplan-Meier curves for progression-free survival (A), and overall survival (B) by treatment The Lancet Oncology 2015 16, 967-978DOI: (10.1016/S1470-2045(15)00139-4) Copyright © 2015 Valle et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 3 Kaplan-Meier curves for overall survival, by number of circulating tumour cells in 7·5 mL whole blood, collected before treatment The Lancet Oncology 2015 16, 967-978DOI: (10.1016/S1470-2045(15)00139-4) Copyright © 2015 Valle et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 4 Kaplan-Meier curves for overall survival, by number of circulating VEGFR2 in the plasma, before treatment The Lancet Oncology 2015 16, 967-978DOI: (10.1016/S1470-2045(15)00139-4) Copyright © 2015 Valle et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 5 Kaplan-Meier curves for overall survival, by concentrations of circulating PDGFbb in the plasma, before treatment Plots show treatment effect by low (A) and high concentrations (B) of PDGFbb at baseline (median 162 pg/mL PDGFbb is the cutoff point), which show evidence of interaction between PDGFbb and treatment. The Lancet Oncology 2015 16, 967-978DOI: (10.1016/S1470-2045(15)00139-4) Copyright © 2015 Valle et al. Open Access article distributed under the terms of CC BY Terms and Conditions